Whalesbook
📉 The Financial Deep Dive
Advanced Enzyme Technologies Limited reported a mixed financial performance for the quarter and nine months ended December 31, 2025 (Q3 FY26).
Quarterly Performance (Q3 FY26 vs Q3 FY25):
Revenue saw a marginal year-on-year (YoY) increase of 2%, reaching ₹1,719 million from ₹1,691 million. However, EBITDA de-grew by 11% YoY to ₹494 million from ₹553 million. Profit After Tax (PAT) presented a positive trend, rising 11% YoY to ₹432 million compared to ₹389 million. The EBITDA margin stood at 29%, and the PAT margin was 25% for Q3 FY26.
Sequential Performance (Q3 FY26 vs Q2 FY26):
On a quarter-on-quarter (QoQ) basis, the company experienced a de-growth across key metrics. Revenue declined by 7% QoQ to ₹1,719 million. EBITDA saw a more substantial decrease of 18% QoQ to ₹494 million, and PAT also decreased by 3% QoQ to ₹432 million.
Nine-Month Performance (9M FY26 vs 9M FY25):
The first nine months of FY26 demonstrated stronger growth. Revenue increased by 15% YoY to ₹5,424 million. EBITDA grew 11% YoY to ₹1,658 million, and PAT showed robust growth of 20% YoY, reaching ₹1,284 million. The EBITDA margin for 9M FY26 was 31%, and PAT margin was 24%.
Full Year Performance (FY25 vs FY24):
The full fiscal year 2025 results were subdued. Revenue grew marginally by 2% YoY to ₹6,369 million. EBITDA declined by 5% YoY to ₹1,944 million, and PAT saw a decrease of 2% YoY to ₹1,340 million. EBITDA margin for FY25 was 31%, down from 33% in FY24, indicating margin compression, and PAT margin decreased from 22% to 21%.
Exceptional Item:
An exceptional item of ₹(112) million was recorded in Q3 FY26 and for the 9M FY26 period, impacting the profit before tax. The specific nature of this item was not detailed.
Segmental and Geographical Performance:
Growth drivers included Animal Nutrition (+22% YoY in Q3, +26% YoY in 9M) and Industrial Bio-Processing (+13% YoY in Q3, +15% YoY in 9M). Human Nutrition was mixed, declining 6% YoY in Q3 but growing 12% YoY in 9M. Geographically, India showed strong 9M growth (+21% YoY), and Asia (ex-India) grew significantly (+60% YoY in 9M). However, the Americas region saw a decline in Q3 (-11% YoY) and 9M (-6% YoY).
Financial Health and Outlook:
The company maintains a strong balance sheet with a Net Worth of ₹14,209 million in FY25 and a very low Net Debt to Equity ratio of 0.02x. However, Return on Equity (ROE) and Return on Capital Employed (ROCE) have seen a declining trend, standing at 9.76% and 11.31% respectively in FY25. Management's focus areas include expanding in Animal Nutrition and Probiotics, developing Bio-Catalysis solutions, and strengthening its position in Baking. Future growth drivers identified include continued R&D investment, geographical expansion, and inorganic acquisitions.
🚩 Risks & Outlook
Risks include the sequential de-growth in revenue and EBITDA, margin compression observed in the full-year results, and the declining trend in ROE/ROCE. The unexplained exceptional item also introduces uncertainty. The performance in the Americas region needs close monitoring. The forward view relies on management's stated growth drivers: R&D, geographical expansion (particularly in India and Asia), and potential inorganic acquisitions, alongside continued focus on high-performing segments like Animal Nutrition and Industrial Bio-Processing.